Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Jennifer Sherr MD, PhD

Jennifer Sherr MD, PhD

Instructor, Pediatrics (Endocrinology), Yale University School of Medicine, New Haven, Connecticut

Dr. Jennifer Sherr is an Instructor in Pediatrics (endocrinology) at Yale University School of Medicine. She attended the University of Medicine and Dentistry New Jersey-Robert Wood Johnson Medical School and subsequently came to Yale Children’s Hospital to complete her pediatric residency.

During her fellowship in endocrinology at Yale University School of Medicine, she was accepted into the Investigate Medicine Program at Yale University Graduate School of Arts & Sciences. The focus of her doctoral thesis was examination of the dysregulated glucagon response early in the course of type 1 diabetes.

Subsequently, her research has focused on artificial pancreas technologies and the use of adjunctive therapy to mitigate postprandial hyperglycemia.


Degrees:

MD: University of Medicine and Dentistry New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ

PhD: Investigative Medicine at Yale University Graduate School of Arts & Sciences


Postgraduate Training:

Residency: Yale New Haven Children’s Hospital Residency Program

Fellowship: Yale University School of Medicine Postdoctoral Fellowship in Pediatric Endocrinology and Metabolism

Research Interests: closed loop systems/artificial pancreas technologies, counterregulatory responses to hypoglycemia, use of adjunctive therapy for type 1 diabetes.